Free Trial
NASDAQ:GALT

Galectin Therapeutics Q2 2024 Earnings Report

Galectin Therapeutics logo
$4.21 -0.04 (-0.94%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Galectin Therapeutics EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.16
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Galectin Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galectin Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Galectin Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 7:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Galectin Therapeutics Earnings Headlines

Q3 EPS Estimate for Galectin Therapeutics Lifted by Analyst
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Galectin Therapeutics Inc. (GALT) - Yahoo Finance
See More Galectin Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT), a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

View Galectin Therapeutics Profile

More Earnings Resources from MarketBeat